Prelude Therapeutics (PRLD) Payables (2019 - 2026)
Prelude Therapeutics (PRLD) posted Payables of $2.1 million for Q1 2026, down 48.05% sequentially from $4.0 million in Q4 2025, and down 64.52% YoY from $5.8 million in Q1 2025.
Prelude Therapeutics (PRLD) Payables (2019 - 2026) Analysis & Trends
Prelude Therapeutics has reported Payables for 8 years, with the latest figure at $2.1 million in Q1 2026.
- Quarterly Payables fell 64.52% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (down 64.52% YoY) and the FY2025 annual result came in at $4.0 million, down 48.49% from the prior year.
- Payables eased to $2.1 million in Q1 2026 per PRLD's latest filing, from $4.0 million in the prior quarter.
- Over five years, Payables peaked at $10.2 million in Q3 2022 and troughed at $2.1 million in Q1 2026.
- A 5-year average of $5.7 million and a median of $5.8 million in 2025 frame the typical range for Payables.
- The sharpest annual moves came in 2024 and 2026: Payables surged 68.82% in 2024, then slumped 64.52% in 2026.
- Over 5 years, Payables stood at $6.8 million in 2022, then sank by 32.42% to $4.6 million in 2023, then jumped by 68.82% to $7.7 million in 2024, then sank by 48.49% to $4.0 million in 2025, then plunged by 48.05% to $2.1 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $2.1 million, $4.0 million, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Prelude Therapeutics | 442.91 Mn | 162.28 Mn | - | 2.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.03 Mn |
| Mar 31, 2026 | 2.07 Mn |
| Dec 31, 2025 | 3.98 Mn |
| Sep 30, 2025 | 2.53 Mn |
| Jun 30, 2025 | 4.96 Mn |
| Mar 31, 2025 | 5.83 Mn |
| Dec 31, 2024 | 7.73 Mn |
| Sep 30, 2024 | 5.92 Mn |
| Jun 30, 2024 | 6.17 Mn |
| Mar 31, 2024 | 5.31 Mn |
| Dec 31, 2023 | 4.58 Mn |
| Sep 30, 2023 | 5.17 Mn |
| Jun 30, 2023 | 5.59 Mn |
| Mar 31, 2023 | 7.08 Mn |
| Dec 31, 2022 | 6.78 Mn |
| Sep 30, 2022 | 10.25 Mn |
| Jun 30, 2022 | 6.27 Mn |
| Mar 31, 2022 | 7.39 Mn |
| Dec 31, 2021 | 7.84 Mn |
| Sep 30, 2021 | 11.06 Mn |